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Abstract
Background: The study is to evaluate the patterns of failure, toxicities and long-term outcomes of aggressive
treatment using 18F-FDG PET/CT-guided chemoradiation plannings for advanced cervical cancer with extensive
nodal extent that has been regarded as a systemic disease.
Methods: We retrospectively reviewed 72 consecutive patients with 18F-FDG PET/CT-detected widespread pelvic,
para-aortic and/or supraclavicular lymph nodes treated with curative-intent PET-guided cisplatin-based extended-field
dose-escalating intensity-modulated radiotherapy (IMRT) and adaptive high-dose-rate intracavitary 3D-brachytherapy
between 2002 and 2010. The failure sites were specifically localized by comparing recurrences on fusion of
post-therapy recurrent 18F-FDG PET/CT scans to the initial PET-guided radiation plannings for IMRT and brachytherapy.
Results: The median follow-up time for the 72 patients was 66 months (range, 3–142 months). The 5-year disease-free
survival rate calculated by the Kaplan-Meier method for the patients with extensive N1 disease with the uppermost
PET-positive pelvic-only nodes (26 patients), and the patients with M1 disease with the uppermost PET-positive
para-aortic (31 patients) or supraclavicular (15 patients) nodes was 78.5 %, and 41.8–50 %, respectively (N1 vs. M1,
p = 0.0465). Eight (11.1 %), 18 (25.0 %), and 3 (4.2 %) of the patients developed in-field recurrence, out-of-field and/or
distant metastasis, and combined failure, respectively. The 6 (8.3 %) local failures around the uterine cervix were all at
the junction between IMRT and brachytherapy in the parametrium. The rate of late grade 3/4 bladder and bowel
toxicities was 4.2 and 9.7 %, respectively. When compared to conventional pelvic chemoradiation/2D-brachytherapy
during 1990–2001, the adoption of 18F-FDG PET-guided extended-field dose-escalating chemoradiation plannings in
IMRT and 3D-brachytherapy after 2002 appeared to provide higher disease-free and overall survival rates with
acceptable toxicities in advanced cervical cancer patients.
Conclusions: For AJCC stage M1 cervical cancer with supraclavicular lymph node metastases, curability can be
achieved in the era of PET and chemo-IMRT. However, the main pattern of failure is still out-of-field and/or distant
metastasis. In addition to improving systemic treatment, how to optimize and integrate the junctional doses between
IMRT and 3D-brachytherapy in PET-guided plannings to further decrease local recurrence warrants investigation.
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Advanced cervical cancer requires multimodal treatment.
Because of the high probabilities of pelvic, para-aortic and
occult supraclavicular lymph node metastasis that is part
of the TNM staging system but not part of the Inter-
national Federation of Gynecology and Obsterics (FIGO)
staging system, pre-treatment lymph node staging by
using [18 F]fluorodeoxyglucose positron emission tomog-
raphy/computed tomography (18F-FDG PET/CT) to
detect potential disease that might have been missed by
conventional imaging has been recommended [1]. A series
of studies demonstrated that at diagnosis, up to 47 % of
cervical patients had lymph node metastasis on PET [2].
The presence of PET-positive lymph nodes may iden-
tify patients who are better treated with cisplatin-based
concurrent chemoradiotherapy (CCRT) to minimize the
risk of increased toxicities associated with a combination
of surgery and radiotherapy (RT) [3, 4]. However, con-
ventional four-field box or anterior-posterior parallel
opposed RT for patients with extensive multiple pelvic/
para-aortic/supraclavicular lymph node metastases is dif-
ficult to escalate dosage to the para-aortic and bulky
sidewall nodes owing to the risk of severe complications
such as enteritis, proctitis and cystitis [5]. Since the
adoption of new RT modalities (eg, intensity-modulated
RT (IMRT), image-guided IMRT (IGRT) and three-
dimension (3D)-brachytherapy results in fewer treatment-
related normal tissue toxicities, dose escalation might
improve local control and even survival by employing
extended-field IMRT/IGRT CCRT that aggressively tar-
gets the lymph node regions according to the highest
level of lymph node involvement detected by PET [6–9].
However, there are yet no trials that compare curative-
intent extended-field CCRT (to cover from the pelvic,
para-aortic to supraclavicular fossa) versus palliative-
intent pelvic-only CCRT. It remains unknown whether
the PET-based treatment guideline regarding radical hys-
terectomy versus definitive CCRT and PET-guided
IMRT/IGRT/brachytherapy planning to increase tumor
coverage and treatment intensity improves survival, or sim-
ply induces the phenomenon of “TNM stage migration”
and “treatment selection bias” in cervical cancer [10].
In this study, we assessed the long-term outcomes,
patterns of failures and toxicities in advanced cervical
cancer patients with extensive FDG-avid pelvic, para-
aortic, and/or supraclavicular metastases but no known
bone and/or visceral disease at diagnosis. They were all
treated with curative-intent extended-field dose-escalating
CCRT by IMRT/IGRT/3D-brachytherapy targeting all
PET-positive lymph node basins and boosting lesions with
standardized uptake values (SUVs) of 2.5 or greater. We
also compared the survival outcomes of invasive cervical
cancer before and after 2002, when 18F-FDG PET/CT was
set up for cancer staging and PET-guided IMRT, IGRTand 3D-brachytherapy plannings became standard and
common practice at our institution with time.
Methods
Patients
This study was approved by the ethics committee of Koo
Foundation Sun-Yat-Sen Cancer Center. We retrospect-
ively reviewed 564 consecutive biopsy-proven cervical
cancer patients with FIGO stage IA2-IVA or IVB that
had para-aortic and/or supraclavicular lymph node
involvement with no known bone and/or visceral metas-
tasis at diagnosis between 1990 and 2010. Written
informed consent was obtained from all patients
included in the study before therapy. This study was per-
formed in accordance with the Declaration of Helsinki
and with national regulations.
Staging
After 2002, patients with bulky IB2, FIGO IIB or higher
stage, or magnetic resonance imaging (MRI)-positive
pelvic lymphadenopathy further underwent 18F-FDG PET/
CT to detect occult extrapelvic metastasis (Additional
file 1: Fig. S1). The extrapelvic foci of increased FDG
uptake on PET were always confirmed by CT- or
sonography-guided or laparoscopic biopsy and/or
cytology. Although the nodal status was determined by
MRI and PET images and even surgical procedures,
results of the MRI- and PET-based AJCC TNM staging
did not alter the initial clinical FIGO stage. However,
treatment strategy and planning were based on the
PET- and MRI-findings.
Curative treatment
Treatment options for early stage patients with FIGO
stage IA2-IIA disease included primary surgery as follows:
modified radical hysterectomy (class II) and pelvic lymph-
adenectomy for IA2; radical hysterectomy (class III) and
pelvic lymphadenectomy for IB1-IIA without oophorec-
tomy for squamous cell carcinoma, or with oophorectomy
for adenocarcinoma; or primary RT without concurrent
chemotherapy for IA2-IB1, or with concurrent chemo-
therapy for IB2-IIA. For patients treated with a primary
surgical approach, post-operative adjuvant RT was admin-
istered if the final pathology findings revealed
intermediate-risk features of lymphovascular invasion or
deep stromal invasion; adjuvant CCRT was administered
if high-risk features of positive surgical margins, patho-
logically involved pelvic nodes, or positive parametrial in-
volvement were observed (Additional file 7: Fig. S6A). For
advanced stage patients with FIGO IIB-IVA or IVB with
para-aortic or supraclavicular lymph node involvement
but no distant organ metastasis, definitive CCRT was the
mainstay of treatment.
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In order to overcome the challenges of intra- and
inter-fraction organ motion, anatomy variations due
to tumor shrinkage, and target dose escalation while
sparing normal tissues during a long course of frac-
tionated RT, the RT planning combined the advan-
tages of conventional external beam 3D-RT, modern
IMRT/IGRT and 3D-brachytherapy techniques to
comprise a 3-phase sequential external beam radi-
ation intervening with adaptive 3D-brachytherapy
(Additional file 1: Fig. S1, Additional file 2: Fig. S2,
Additional file 3: Fig. S3, Additional file 4: Fig. S4,
Additional file 5: Fig. S5). Image-guidance and adap-
tive RT with repeated CT simulation were commonly
used together. During dose escalation by IGRT, daily
cone-beam CT was used to not only guide re-
position by simple couch shifts but also decide to
make a new adaptive plan to prevent suboptimal
treatment.
Advanced cervical cancer patients all received extended-
field 3D-RT (10 or 18 MV photons, 1.8 Gy per fraction, 1
fraction per day, 5 fractions per week) from the pelvis to
the para-aortic area, depending on their work-up, with
concurrent weekly cisplatin (40 mg/m2) for 6 cycles. For
patients with chronic renal failure or severe baseline neur-
opathy which could not be improved by a ureteral stent or
nephrostomy tube placement, we treated these patients
with weekly carboplatin dosed at area under the curve
(AUC) 2 for 6 cycles. All patients underwent a pre-
treatment computed tomography (CT)-based simulation
with a full bladder and an empty rectum. Delineation of
the cervical tumor, enlarged lymph nodes, uterus, bladder,
rectum, intestine, femurs, and kidneys was based on dosi-
metric CT scans acquired with axial 3–5 mm thickness.
For patients with extensive lymph node involvement, the
PET scans and the RT simulation CT images were fused
using point and anatomic matching to allow contouring
all of the metabolically active lymph nodes with SUVs of
2.5 or greater at the delayed phase. A 0.5-cm to 1.0-cm
margin was added to the PET-detected or gross nodes to
create the clinical target volume (CTV). An extra 0.5-cm
to 1-cm was added to CTV to form a planning target
volume (PTV). Patients underwent an additional CT
simulation for adaptive IMRT/IGRT re-planning after
4140–4500 cGy. For IMRT planning, the lateral bound-
ary of parametrial CTV was at the pelvic side wall and
the medial boundary of parametrial CTV abutted the
uterus, cervix and vagina though the superior and infer-
ior boundaries might vary (Additional file 3: Fig. S3).
IMRT boost was used after 4500 cGy to treat PTV cov-
ering the para-aortic nodes, pelvis and parametria up to
5400 cGy in 30 fractions while sparing the intestine, kid-
neys, spinal cord, bladder, rectum, and femoral neck.
IGRT was used after 5400 cGy to boost CTV coveringthe para-aortic and pelvic nodes with 18F-FDG SUVs of
4.5 or greater at the delayed phase of PET up to 5940–
6480 cGy in 33–36 fractions. Chemotherapy was withheld
when the white blood cell count was <1500/mL or the
platelet count was <80,000/mL, and restarted after recov-
ery from such low cell counts. Ninety percent of patients
with definitive CCRT received at least four cycles of cis-
platin or carboplatin.
For confluent bulky supraclavicular lymph node metasta-
sis with pathology confirmation (Additional file 5: Fig. S5),
a second set of PET-guided RT treatment planning
included irradiation of the bilateral lower neck, supra-
clavicular fossa and upper mediastinum by antero-
posterior opposed parallel portals (up to 4500 cGy in
25 fractions over 5 weeks), and then an IMRT boost
for CTV covering the PET-detected supraclavicular/
mediastinum nodes with SUVs of 4.5 or greater at the
delayed phase up to 5940–6120 cGy in 33–34 fractions
with sparing of the heart, esophagus, and spinal cord.
For the occult supraclavicular metastasis (Additional
file 1: Fig. S1), the RT field would not include the
upper mediastinum. For patients with good perform-
ance status and no anemia or body weight loss, the
supraclavicular metastasis was irradiated at the same
time with para-aortic/pelvic RT (Additional file 5: Fig. S5);
otherwise, it would be irradiated sequentially.Adaptive image-based high-dose-rate intracavitary
3D-brachytherapy
After 4500 cGy external beam irradiation, adaptive high-
dose-rate PET-guided intracavitary 3D-brachytherapy using
an iridium-192 source and Henschke afterloading applica-
tors was performed once or twice weekly under general
anesthesia. Patients underwent a pelvic CT scan acquired
with axial 1 mm thickness right after implantation. The
images were then transferred onto Oncentra® platforms
(Nucletron Medical Systems, an Elekta company,
Stockholm, Sweden). The PET scans plus MRI T2WI taken
before treatment and the post-implantated CT images were
fused using anatomic matching. The ICRU-38 point-A, the
initial tumor extent and the entire uterine cervix were con-
toured and summed together as CTV. The CTV was fur-
ther defined as high risk (HR)- and intermediate risk (IR)-
CTVs based on relatively different intensity of SUVs of 18F-
FDG PET (HR defined as SUVs of 4.5 greater at the delayed
phase and IR defined as SUVs of 2.5–4.5 at the delayed
phase). Organs at risk (rectum, sigmoid and bladder) and
ICRU bladder and rectum points were also contoured. The
dose prescription was adjusted to deliver at least 5–7 Gy
per fraction using 4–6 insertions to cover both point-A and
90–100 % of the PET-based HR/IR-CTV, based on the dose
limit derived from the simulated 3D computer treatment
plan for the rectum, sigmoid and bladder, using both the
Table 1 Clinical characteristics and FIGO stage distribution of 72
cervical cancer patients with extensive PET-positive pelvic,
para-aortic, and/or supraclavicula node disease treated with
curative-intent PET-guided extended-field chemo-IMRT/3D-
brachytherapy











No. of Patients 26 31 15
Age at diagnosis, years
Median 50.9 53.1 52.5
Range 32.3–73.6 29.8–73.8 36.9–68.7
Tumor histology (%)
Squamous cell carcinoma 26 (100) 28 (90.3) 12 (80.0)
Adenocarcinoma 0 (0) 2 (6.5) 3 (20)
Adenosquamous 0 (0) 1 (3.2) 0 (0)
FIGO clinical stage
IA2-IB2 5 (19.2) 8 (25.8) 4 (26.7)
IIA-IIB 18 (69.2) 18 (58.1) 9 (60.0)
IIIA-IIIB 3 (11.5) 3 (9.7) 1 (6.7)
IVA 0 (0) 2 (6.5) 1 (6.7)
Abbreviations: FIGO International Federation of Gynecology and Obsterics
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GEC–ESTRO [11, 12].
Combination of external beam radiation and
brachytherapy
By applying the linear quadratic model to transform
brachytherapy and external beam absolute doses to a 2-
Gy equivalent dose (EQD2,), we could sum the total
EQD2 and generate dose volume histograms of CTV
and organs at risk. In our protocol, the 1st brachytherapy
was performed just after completion of the initial 3D-RT
and before the start of IMRT boost so that we could fuse
the simulated CT scans of the 3D-RT, IMRT and brachy-
therapy plannings in the middle of RT course for final
total dose adjustment based on the dose constraints to
organs at risk. In order to achieve the ESTRO recom-
mended CTV levels and dose constraints for organs at
risk, we repeatedly adjusted the parameters of dose con-
straints for organs at risk in IMRT plannings, and manually
reiterated brachytherapy dose-optimization to combine ex-
ternal beam radiation with brachytherapy. Our goal was to
deliver at least total 60 Gy EQD2 (α/β = 10) to 90 % of the
IR-CTV and a minimum of total 85 Gy EQD2 (α/β = 10) to
90 % of the HR-CTV while limiting organs at risk to a min-
imal dose of 75 Gy EQD2 (α/β = 3) to the maximally
exposed 2 cm3 of the rectal wall and of the sigmoid wall,
and 85 Gy EQD2 (α/β = 3) to the 2 cm3 of the blad-
der wall (Additional file 1: Fig. S1, Additional file 2:
Fig. S2, Additional file 3: Fig. S3, Additional file 4:
Fig. S4, Additional file 5: Fig. S5).
Follow-up
Patients had regular follow-up of physical examinations,
Pap tests, and tumor markers (SCC and CEA) approxi-
mately every 2–3 months for the first 12 months, every
3–4 months for the following 2 years, every 4–6 months
for the next 2 years, and then yearly. A repeat pelvic
MRI and/or abdominal/chest CT scans were performed
2 months after completing treatment to evaluate re-
sponses, and then annually. A repeat 18F-FDG PET/CT
was performed when warranted by MRI, tumor markers,
clinical examination or symptoms. The sites and timing
of any recurrence were recorded. NCI Common Ter-
minology Criteria for Adverse Events (CTCAE v3.0) was
used to score the maximum toxicity.
Statistical analysis
Survival rates were measured from the beginning of
treatment, and calculated using the Kaplan-Meier method.
The test of equivalence of estimates of overall survival or
disease-free survival between the periods 1990–2001 and
2002–2010 was performed using the log-rank test. A value
of p < 0.05 was set as the threshold for significance.Results
Impacts of 18F-FDG PET/CT-guided radiation planning on
patterns of failure
We analyzed the treatment results of 72 consecutive ad-
vanced cervical cancer patients with extensive pelvic
(more than two or bilateral pelvic lymph node metasta-
ses), para-aortic, and/or supraclavicular nodes with no
known bone and/or visceral metastasis at diagnosis, who
were all staged by clinical FIGO system, pelvic MRI and
whole body 18F-FDG PET/CT scans between 2002 and
2010 (Table 1 and Additional file 1: Fig. S1). FIGO stage
II (62.5 %), PET-based AJCC stage M1 (para-aortic and/
or supraclavicular lymph node involvement) (63.9 %),
and squamous cell carcinoma (86.8 %) were the most
common clinical stages and pathology. They were all
treated by PET-guided cisplatin-based extended-field
dose-escalating external beam radiation and adaptive
3D-brachytherapy with curative intent (Additional file 1:
Fig. S1, Additional file 2: Fig. S2, Additional file 3: Fig. S3,
Additional file 4: Fig. S4, Additional file 5: Fig. S5).
The median follow-up time for the 72 patients was
66 months (range, 3–142 months). The 5-year MRI-
based disease-free survival or progression-free survival
in patients with the uppermost PET-positive pelvic (26
patients), para-aortic (31 patients), and supraclavicular
(15 patients) nodes were 78.5, 41.8, and 50 %,
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para-aortic and/or suparclavicular nodal disease (46
patients), p = 0.0465) (Fig. 1 and Table 2). On the other
hand, the bone and/or visceral metastasis rates for
patients with the uppermost PET-positive pelvic, para-
aortic, and supraclavicular nodes were 23.1, 32.3, and
33.3 %, respectively. These findings are consistent with
the TNM system, which stages pelvic lymph node me-
tastasis as N1, and para-aortic or supraclavicular lymph
node metastasis as M1. Most recurrences developed 1–3
years after treatment.
In order to assess the patterns of failure, the pre-
treatment planning CT scans for PET-guided IMRT and
brachytherapy were co-registered and fused to the post-
treatment 18F-FDG PET/CT scans in patients with
recurrence. Recurrent tumors were mapped to the initial
RT treatment fields and dose distribution. The main pat-
tern of failure was still out-of-field and/or distant metas-
tasis (N1, 23.1 % vs. M1, 32.6 %) (Fig. 2a). The rate of
in-field failure (within 4500–6120 cGy coverage) in the
26 patients (N1) with numerous pelvic-only nodes and
the 46 patients (M1) with widespread para-aortic and/or
supraclavicular nodes was 11.5 and 17.4 %, respectively.
When external beam radiation and intracavitary brachy-
therapy doses transformed to EQD2 (equivalent dose in
2-Gy per fraction) were combined, we found that the 6
local recurrence around the uterine cervix all fell at the
junctional zone between brachytherapy (EQD2 85Gy)
and IMRT (EQD2 60 Gy) in the uterosacral and cardinal
ligaments or parametrium (Fig. 2b).
Toxicities
Although the 72 patients completed the curative-intent
treatment without major interruption within 56–63 days,
almost all of these patients experienced a transient acuteFig. 1 The effects of employing integrated 18F-FDG PET/CT staging, modern m
and concurrent chemotherapy for treatment of advanced cervical cancer
Kaplan-Meier disease-free survival estimates for the 72 patients with exten
lymph node involvement after curative-intent treatment. LAP, lymphadengrade 2–3 hematologic toxicity with white blood cell
count falling to 1000-3000/mm3 during the final week of
treatment (Additional file 5: Fig. S5B), as well as man-
ageable grade 2 gastrointestinal effects with nausea,
vomiting, and/or diarrhea during the treatment course.
The late grade 3/4 sequelae were urinary complications
in 3 patients (4.2 %) and rectal or bowel complications
in 7 patients (9.7 %) (Table 3), suggesting no evidence of
excessive severe treatment-related toxicities in our study
when compared with the previous reports regarding cer-
vical cancer with pelvic CCRT using a standard RT dos-
age and technique [13–15].Improved survival of advanced cervical cancer with time
in the era of PET and chemo-IMRT
The year 2002 represents a new era in which our insti-
tution started to adopt the PET-guided IMRT and 3D-
brachytherapy techniques for advanced cervical cancer
patients. Thus, we analyzed whether survival of advanced
cervical cancer patients was improved with time after
2002 at our institution.
The analysis included all 564 consecutive patients
with newly diagnosed invasive cervical cancer, includ-
ing FIGO IA2-IVA and IVB without bone/visceral
metastasis, at our institution from January 1990 to
December 2010 (Additional file 6: Table S1). The two
“1990–2001” and “2002–2010” groups featured similar
age, histology and stage distribution. The 564 patients
were divided into two groups to assess changes in sur-
vival outcome between 1990–2001 (229 patients) and
2002–2010 (335 patients). The median follow-up for
all patients was 89.9 months (range, 1–249.2 months);
the median follow-up was 147.5 months (range, 1–
249.2 months) for patients during 1990–2001, andulti-modalities of radiotherapy (3D-RT, IMRT, IGRT, and 3D-brachytherapy)
with extensive nodal disease but no visceral metastasis at diagnosis.
sive PET-positive lymph nodes grouped by their highest level of
opathy; SC, supraclavicular
Table 2 Patterns of failure and survival in cervical cancers with pelvic, para-aortic and/or supraclavicular lymph node metastasis
treated with PET-guided extended-field dose-escalating chemo-IMRT/3D-brachytherapy
Outcomes Pelvic LAP Paraaortic LAP SC LAP Total (%)
Dead/Total 5/26 12/31 6/15 23/72 (31.9)
In-field failure-only (cervix, lymph nodes) 2 5 1 8 (11.1)
Out-of-field failure-only (lymph node, bone and/or visceral metastases) 5 8 5 18 (25.0)
Both failures 1 2 0 3 (4.2)
Survival
1-year DFS (%) 91.7 89.9 75.0 –
3-year DFS (%) 78.5 55.8 75.0 –
5-year DFS (%) 78.5 41.8 50.0 –
Abbreviations: CCRT concurrent chemoradiotherapy, IMRT/IGRT intensity-modulated and image-guided radiotherapy, LAP lymphadenopathy, DFS disease-free sur-
vival, PET fluorodeoxyglucose position emission computed tomography
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2002–2010.
The 5-year and 8-year overall survival (OS) for patients
were 70.7 and 65.9 % in 1990–2001 versus 77.1 and
75.2 % in 2002–2010, respectively (p = 0.0311) (Fig. 3a).
The assignment of either surgery or RT as a primary mo-
dality in corresponding FIGO stages (radical hysterectomy
plus lymph node dissection + −adjuvant therapy for FIGO
stage IA2-IIA and definitive RT + −chemotherapy for
FIGO stages IIB-IVB) were similar or identical between
1990–2001 and 2002–2010 (Fig. 3b). However, the RTFig. 2 Patterns of failure after 18F-FDG PET-guided RT planning. Pre-treatme
are fused to post-treatment recurrent 18F-FDG PET/CT scans to map the rec
The doses of external beam radiation and brachytherapy are transformed t
field recurrence and distant metastasis. RT dose distribution is demonstrate
by a white arrow. Note that the post-RT in-field structures show lower met
recurrence. Note that the FDG-avid recurrent cervical tumor (white arrow) con
60 Gy) and brachytherapy (EQD2 85 Gy) in the parametriumtechnique and dosage were different between 1990–2001
and 2002–2010. We then quantified and compared the
relative magnitude of OS improvements in each corre-
sponding FIGO stage between 1990–2001 and 2002–2010
(Fig. 3c). Our results consistently demonstrated that the
clinical FIGO I-IV staging was still prognostic after treat-
ment. There was no difference between the two periods
regarding survival outcome from 1 to 8 years in FIGO
stage I patients for whom surgery was the major treat-
ment. In contrast, for FIGO stage II patients for whom RT
was the major modality, the survival rates at 3–8 yearsnt combined RT planning scans of 3D-RT, IMRT and 3D-brachytherapy
urrent tumors in the initial RT treatment fields and dose distribution.
o EQD2 (equivalent dose to a 2-Gy fraction) for combination. a Out-of
d by colors. The lung metastasis confirmed by pathology is indicated
abolic activity as compared to those in the pre-RT scan. (b) In-field
firmed by pathology is located at the junctional zone of IMRT (EQD2
Table 3 Grade 3/4 (CTCAE v3.0) bladder and bowel late
complications after PET-guided extended-field dose-escalating
chemo-IMRT/3D-brachytherapy








Bladder – – – 3 (4.2)
Cystitis 0 1 1 2
Vesicovaginal
fistula
0 1 0 1
Bowel – – – 7 (9.7)
Rectal ulcer 1 0 0 1
Proctitis 1 0 0 1
Rectovaginal
fistula
1 1 1 3
Bowel
obstruction
0 1 1 2
Abbreviations: CTCAE v3.0 common terminology criteria for adverse events,
version toxicity, IMRT/IGRT intensity-modulated and image-guided radiother-
apy, PET fluorodeoxyglucose position emission computed tomography
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extended-field dose-escalating modern RT during 2002–
2010 than in those treated with conventional pelvic RT
during 1990–2001. Thus, our results indicated that the
survival improvement after 2002 might not be related to
surgery but should be associated with RT. Interestingly,
after 2002 the improved OS rate of clinical FIGO II stage
patients was very similar to that of PET-based T1-
4aN1M0 stage IIIB-IVA disease (Figs. 1 and 3c). The
benefit of para-aortic extended-field RT after 2002 was in
line with the 10–25 % prevalence of para-aortic lymph
node metastasis in locally advanced cervical cancer, which
was also consistent with the results of previous studies
that demonstrated prophylactic extended-field IMRT with
elective para-aortic irradiation improved survival in cer-
vical cancer with PET-positive pelvic lymph nodes and
PET-negative para-aortic lymph nodes [16, 17]. However,
most of the FIGO stage III and IV patients treated by
dose-escalating RT on lesions with high SUVs of PET dur-
ing 2002–2010 only exhibited delayed disease progression,
and just showed a better survival trend within 3 years than
the same FIGO stage patients treated during 1990–2002.
Nearly one third of the patients with FIGO stage III to
IVA in 1990–2001 or 2002–2010 developed distant metas-
tases 1–3 years after treatment.
Because CCRT was a curative modality for advanced
cervical cancer (FIGO stage IB2 to IVA) [13–15], in a spe-
cific comparison of the CCRT groups between 1990–2001
(FIGO-based conventional pelvic CCRT/2D-brachyther-
apy) and 2002–2010 (PET-guided extended-field dose-
escalating chemo-IMRT/3D-brachytherapy), we found
that the 8-year OS rate in advanced cervical cancer
patients greatly improved from 41.2 % in 1990–2001 to
70.1 % in 2002–2010 (p = 0.0015) (Fig. 3d). However, it isunclear whether the survival benefit found in this retro-
spective study was due to better 18F-FDG PET/CT-staging
or more aggressive treatment by modern RT modalities,
or both (Additional file 7: Fig. S6).
Discussion
We used data from our institutional cancer registry
during the period from 1990 to 2010 to examine the
trend toward improved survival of patients with invasive
uterine cervical cancer after curative-intent treatment.
We showed that after 2002, patients with advanced
cervical cancers experienced OS improvement with the
PET-guided extended-field dose escalating IMRT/IGRT
CCRT plus adaptive high-dose-rate image-based intra-
cavitary 3D-brachytherapy. The relative magnitude of
OS improvement was greatest in patients with FIGO
stage II and patients with extensively PET-detected node
metastases.
According to historical data, the risks of para-aortic
and supraclavicular lymph node metastasis could be up
to 21 and 7 %, respectively, for FIGO stage II patients
[2]. However, at our institution in 1990–2001, it was dif-
ficult to detect occult lymph node metastases without
PET, and without IMRT/IGRT even para-aortic and
supraclavicular lymph node involvement was often
treated with relatively lower RT doses owing to the fear
of organ toxicity and incurable potential. The RT dosage
for the metastatic pelvic, paraaortic and supraclavicular
nodes was escalated to 5940–6480 cGy in 33–36 frac-
tions by IMRT/IGRT in 2002–2010 in contrast to only
5040–5400 cGy in 28–30 fractions by a conventional 4-
field Box or 3-D technique used in 1990–2001. Although
in our studies the outcomes for patients with PET-
positive para-aortic or supraclavicular lymph node me-
tastases after extended-field chemo-IMRT-brachytherapy
dose escalation CCRT are still worse than the outcomes
for patients with metastatic lymph nodes confined in the
pelvis, they are better than outcomes for patients with
bone, lung, or liver metastases [18–23], with approxi-
mately 40–50 % of patients still living with progression
free of disease at 5 years at our institution. Moreover,
when compared with historical data showing event-
free survival rates at 3 years in cervical patients with
PET-detected para-aortic, and with supraclavicular in-
volvement were only 40, and 0 %, respectively, the
disease-free survival outcomes at 3 years in our patients
with PET-detected M1 disease (para-aortic and/or supra-
clavicular metastasis) but no known bone and/or visceral
metastasis at diagnosis were greatly improved to 55.8–
75 % after PET-guided extended-field dose-escalating
chemo-IMRT-brachytherapy [2]. The results imply an as-
sociation between improvement of survival of a subset of
AJCC stage M1 cervical cancer patients and advance-
ments in PET staging and modern PET-guided chemo-
Fig. 3 Improved survival of cervical cancer with time in the era of 18F-FDG PET/CT and chemo-IMRT/IGRT/3D-brachytherapy: a 20-year analysis including
consecutive 564 patients during 1990–2010 in one institution. a The overall survival rates for cervical cancer patients (FIGO IA2-IVA, and IVB without visceral
metastasis) diagnosed at our institution from 1990 to 2010 are calculated by the Kaplan-Meier method and stratified by treatment year. (b) Comparison of
the distribution of treatment modalities in each corresponding International Federation of Gynecology and Obstetrics (FIGO) stage, 1990–2001
vs. 2002–2010. RT, radiotherapy; CT, chemotherapy. (c) Kaplan-Meier survival estimates for patients with curative treatment are stratified by International
Federation of Gynecology and Obstetrics (FIGO) stage and treatment year. (d) Kaplan-Meier survival estimates for advanced cervical cancer patients
treated with definitive concurrent chemoradiation (CCRT) stratified by treatment year (conventional pelvic CCRT plus 2D brachytherapy in 1990–2001
vs. 18F-FDG PET-guided extended-field dose-escalating chemo-IMRT-brachytherapy in 2002–2010)
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evaluate re-grouping patients with para-aortic and/or
supraclavicular disease in the same stage IVB category as
patients with distant bone and/or visceral organ diseases.
In addition to the predominant pattern of out-of-
field recurrences and distant organ metastases in
twenty-one (29.2 %) of the patients with pelvic, para-
aortic and/or supraclavicular nodes after PET-guided
extended-field dose-escalating chemo-IMRT, there
were still six patients (8.3 %) developing recurrence
around the uterine cervix despite the advances in
PET-guided IMRT/3D-brachytherapy. Failures out of
RT fields could represent insensitive 18F-FDG PET/
CT for tumor detection before treatment and ineffect-
ive systemic chemotherapy, whereas in-field failures
may imply resistant tumors or insufficient RT dose.
Because brachytherapy has a feature of rapid dose
fall-off, it is crucial to know if the local recurrences
are close to or at the edge of the brachytherapy target
volume that is defined by SUVs of 18F-FDG PET. De-
lineation of spatial relationship between recurrent
tumor sites, external beam RT fields and brachyther-
apy dose-gradient margins is challenging. We com-
pared the location of recurrences on post-therapy 18F-
FDG PET/CT scans to the integrated EQD2 RT dose
distribution from the initial external beam RT and
brachytherapy planning scans. The findings of almost
all local failures within or around the junctional zone
between brachytherapy (EQD2 85 Gy) and IMRT
(EQD2 60 Gy) in the bulky cervical tumor edge and
involved parametrium seem to imply insufficient dose.
Thus, for high-risk patients for local recurrence by
evaluation of PET-guided IMRT/intracavitary brachy-
therapy plannings, electively additional interstitial
brachytherapy to the risky parametrium may be con-
sidered; otherwise, salvage modified radical hysterec-
tomy following CCRT may increase morbidity.
However, there is yet no optimization method that in-
tegrates IMRT and brachytherapy to match the dose
junction to further boost up tumor dosage without
concern of increasing normal tissue toxicities. More-
over, because organ motions of the uterus, bladder,
and rectum, and changes in target volume during
treatment are significant during cervical cancer treat-
ment, deformable image registration may be more
feasible and acceptable for assessing cumulative doses
to the tumor and organs at risk in the combination
of external beam RT and fractionated brachytherapy.
This is a retrospective study, thus suffering from
potential biases. Better supportive care, enhanced
multi-disciplinary team cooperation, and greater
compliance with updated evidence-based cancer
treatment guidelines should also be the likely factors
that improved treatment outcomes in the modernmanagement of cervical cancer. Our results show
that clinical FIGO staging is still prognostic, and
treatment strategy and planning should be based on
the PET staging system and modern RT techniques
to maximize curable potential and minimize toxic-
ities. However, adoption of a new facility always
raises the concern of a Will Rogers phenomenon,
which refers to the stage-specific improved survival
of patients with cancer by reclassifying them into dif-
ferent prognostic groups owing to the recognition of
more subtle disease manifestations through new diag-
nostic modalities [24]. The Will Rogers phenomenon
results in stage migration, which could exhibit im-
proved prognosis without affecting actual survival.
Thus, prospective clinical trials comparing manage-
ment with or without extended-field dose-escalating
chemo-IMRT-brachytherapy based on 18F-FDG PET/
CT findings and plannings are warranted.
Because cervical cancer patients with extensive lymph
node involvement are still at high risk of distant metas-
tasis even after 18F-FDG PET-guided extended-field
dose-escalating treatment, we may need to think about
not only other molecular imaging-based anatomic plan-
nings but also tumor biology-based systemic approaches,
such as targeting the signaling and/or immune check-
point pathways that affect human papilloma virus-
related oncogenesis and cancer progression [25, 26].Conclusions
This study covers the integration of radiation therapy
into multimodal treatment approaches in advanced
cervical cancer with extensive nodal involvement. We
show that improved survival of advanced cervical can-
cer with time at our institution is correlated with
adoption of PET-guided extended-field dose escalating
chemo-IMRT and 3D-brachytherapy boost. Although
clinical FIGO staging is still prognostic, treatment
strategy and planning should be based on modern
PET imaging staging and radiation techniques to
maximize curable potential and minimize toxicities.
Our results indicate that although advanced cervical
cancer with extensive nodal extent has been regarded
as a systemic disease by AJCC staging, curability with
acceptable toxicities for the M1 stage can still be
achieved in near 50 % of the patients treated with
modern radiation techniques based on 18F-FDG PET/
CT findings. However, the main pattern of failure was
still out-of-field and/or distant metastasis in 30 % of
the patients. In addition to improving systemic treat-
ment, how to optimize the dose junction between
IMRT and brachytherapy in PET-guided plannings to
further decrease local recurrence also warrants
investigation.
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Additional file 1: Figure S1. Two Parallel Staging Systems for
Advanced Cervical Cancer. (DOC 4920 kb)
Additional file 2: Figure S2. Flow-chart of curative-intent treatment
for advanced cervical cancer patients with extensive nodal disease but
no known visceral metastasis in the era of PET and IMRT at our institution.
(DOC 71 kb)
Additional file 3: Figure S3. PET-guided RT planning for a locally bulky
FIGO IB2 cervical cancer with multiple FDG-avid pelvic-only nodes. The
relatively different intensity of standardized uptake values (SUVs) of 18
F-FDG PET were used to delineate HR- and IR-clinical target volumes
(CTVs) ((high risk defined as SUVs of 4.5 greater at the delayed phase and
intermediate risk defined as SUVs of 2.5–4.5 at the delayed phase). A
representative of fusion between pre-therapy PET and post-implantated
CT scans at time of the 1st brachytherapy after concurrent chemoradiation
of 4500 cGy with one tandem and two ovoid applicators inserted into the
uterus and vaginal fornix, respectively. The 3D RT, IMRT and brachytherapy
doses are transformed to EQD2 (equivalent dose of 2-Gy fraction) for
combination. Adding to external beam radiation, the brachytherapy
planning aimed to deliver a minimum of total EQD2 85 Gy to 90 %
of the HR/IR-CTVs in 5 fractions (Frs). HR-CTV: FDG-avid dark color;
IR-CTV: FDG-avid light color; B, FDG-avid bladder. Note that the green,
red and yellow arrows indicate the area only receiving external beam
radiation, the junction of IMRT and brachytherapy, and the overlapping of
IMRT and brachytherapy, respectively. There is yet no optimization method
to match the dose junction between IMRT and brachytherapy.
(DOC 399 kb)
Additional file 4: Figure S4. PET imaging aids in target volume
delineation for radiotherapy (RT) planning in a FIGO IIIB cervical cancer
patient with extensive lymph node metastases in the pelvic and para-aortic
areas. (A) External beam planning. A representative RT treatment plan
includes the combination of an initial 4-field box technique (4500 cGy/25
frs) to the whole pelvis and para-aortic area with a subsequent IMRT boost
with central pelvic sparing (900 cGy/5 frs) to the PET-detected lymph node
basisn and parametria, and a final IGRT boost to the high SUV lymph nodes
(720 cGy/4 frs). (B) PET-based intracavitary 3D brachytherapy planning to
deliver at least 500 cGy to 90 % of the PET-definied HR-CTV (as SUVs of 4.5
greater at the delayed phase) and IR-CTV (as SUVs of 2.5–4.5 at the delayed
phase). The dark yellow arrow indicates a double-J in the right hydroureter.
Ure, ureter; B, bladder; R, rectum; Si, sigmoid. (DOC 448 kb)
Additional file 5:Figure S5. The integrated 18 F-FDG PET/CT staging,
modern multi-modalities of radiotherapy (RT) planning and concurrent
chemotherapy for treatment of an advanced cervical cancer patient with
extensive pelvic, para-aortic and supraclavicular nodal diseases but no visceral
metastasis at diagnosis. (A) An integrated concurrent chemoradiotherapy
(CCRT) showing a combination of PET-guided cisplatin-based extended-field
dose-escalating IMRT/IGRT and adaptive high-dose-rate (HDR) image-based
intracavitary 3D brachytherapy. External beam RT (EBRT) and brachytherapy
doses are transformed to EQD2 (equivalent dose of 2-Gy fraction) for
combination. HR-CTV: SUVs of 4.5 greater at the delayed phase of
PET; IR-CTV: SUVs of 2.5-4.5 at the delayed phase of PET; R, rectum; B,
bladder; Si, sigmoid. (B) The hematologic toxicity profile of the patient during
the extended-field CCRT. (DOC 258 kb)
Additional file 6: Table S1. Clinical characteristics and distribution of
treatment modalities of 564 consecutive cervical cancer patients without
visceral metastasis diagnosed in1990-2010. (DOC 38 kb)
Additional file 7: Figure S6. Clinical impacts of concurrent
chemotherapy, IMRT and PET on survival of cervical cancer patients. The
year 2002 represents a point at which our institution started to use 18
F-FDG PET/CT for staging, planning and/or follow-up in cancer patients,
and commonly adopted the IMRT technique for cancer patients who
needed RT. (A) Proportions of patients alive and free of disease at 8 years
after treatment with a specific or combined treatment modality during
the periods 1990–2001 and 2002–2010.The disease-free survival of
patients treated by conventional RT in 1990–2001 was compared to that
of patients treated by IMRT in 2002–2010 (conventional RT vs. IMRT). The
disease-free survival of patients treated with concurrentchemoradiotherapy (CCRT) was compared to that of patients treated with RT
alone (CCRT vs. RT alone). * represents p< 0.05 (Chi-squared test). S, surgery;
RT, radiotherapy; C, chemotherapy; CCRT, concurrent chemoradiotherapy. (B)
Kaplan-Meier survival estimates for invasive cervical cancer patients with or
without PET or PET/CT for staging, planning, follow-up, and/or re-staging
between 1990 and 2010. Although patients treated in 1990–2001 did not have
pre-treatment PET staging, a portion of these patients had PET/CT for
follow-up or re-staging when recurrence occurred after 2002. For
patients treated in 2002–2010, if MRI did not show significant pelvic
(cN1)/para-aortic (cM1) lymphadenopathy, parametrial involvement
(cT2b), hydronephrosis (cT3b) and/or bladder/rectal invasion (cT4), no
PET/CT was recommended according to our hospital guideline. For
patients with recurrence noted after 2002, if PET/CT did not reveal
distant metastasis, salvage surgery was performed if feasible.
(DOC 51 kb)
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